Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease
Conclusions
DM patients with CKD stages 3–4 had elevated PMPs, EMPs and MMPs compared with DM patients with normal GFR. Simvastatin reduced procoagulant MPs, MMPs and PMPs in DM-CKD patients, suggesting a beneficial reduction of hypercoagulability in this high-risk patient group. Differences between DM-CKD and DM-only patients were counteracted by LLT.
Source: Nephrology Dialysis Transplantation - Category: Urology & Nephrology Authors: Almquist, T., Mobarrez, F., Jacobson, S. H., Wallen, H., Hjemdahl, P. Tags: Chronic Kidney Disease Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Dialysis | Endocrinology | Heart | Kidney Transplant | Kidney Transplantation | Simvastatin | Statin Therapy | Study | Transplants | Urology & Nephrology | Vytorin | Zetia | Zocor